Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation.
A new immunoblot assay, composed of four Epstein-Barr virus (EBV)-encoded recombinant proteins (virus capsid antigen [VCA] p23, early antigen [EA] p138, EA p54, and EBNA-1 p72), was compared with an immunofluorescence assay on a total of 291 sera. The test was accurate in 94.5% of cases of primary EBV infection, while an immunoglobulin G anti-VCA p23 band with strong intensity correlated with reactivation.
Buisson
M
M
Laboratoire de Virologie Médicale Moléculaire, RHAP-CNRS, Faculté de Médecine, 38043 Grenoble, France. Marlyse.Buisson@ujf-grenoble.fr
Fleurent
B
B
Mak
M
M
Morand
P
P
Chan
L
L
Ng
A
A
Guan
M
M
Chin
D
D
Seigneurin
J M
JM
D000956:Antigens, Viral / Q000032:analysis / Q000276:immunology*; D006566:Herpesviridae Infections / Q000175:diagnosis* / Q000821:virology*; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D015151:Immunoblotting / Q000379:methods*; D011994:Recombinant Proteins / Q000032:analysis / Q000276:immunology; D012680:Sensitivity and Specificity; D012698:Serologic Tests / Q000379:methods; D014412:Tumor Virus Infections / Q000175:diagnosis* / Q000821:virology*
D000956:Antigens, Viral; D011994:Recombinant Proteins